tiprankstipranks
Trending News
More News >
Gilead Sciences (GILD)
NASDAQ:GILD
US Market

Gilead Sciences (GILD) Stock Forecast & Price Target

Compare
13,281 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
20Ratings
Strong Buy
15 Buy
5 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$120.47
▲(7.12%Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $120.47 with a high forecast of $140.00 and a low forecast of $92.00. The average price target represents a 7.12% change from the last price of $112.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","141":"$141","80.25":"$80.3","100.5":"$100.5","120.75":"$120.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$120.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,80.25,100.5,120.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.91,111.30153846153846,113.69307692307692,116.08461538461538,118.47615384615385,120.86769230769231,123.25923076923077,125.65076923076923,128.0423076923077,130.43384615384616,132.82538461538462,135.21692307692308,137.60846153846154,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.91,109.79923076923076,110.68846153846154,111.5776923076923,112.46692307692308,113.35615384615384,114.24538461538461,115.13461538461539,116.02384615384615,116.91307692307691,117.80230769230769,118.69153846153846,119.58076923076923,{"y":120.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.91,107.60923076923076,106.30846153846153,105.00769230769231,103.70692307692308,102.40615384615384,101.10538461538461,99.80461538461539,98.50384615384615,97.20307692307692,95.90230769230769,94.60153846153847,93.30076923076923,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.94,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.97,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.63,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.08,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.66,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.51,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$140.00Average Price Target$120.47Lowest Price Target$92.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GILD
TipRanks AITipRanks
Not Ranked
TipRanks
$119
Buy
5.82%
Upside
Reiterated
05/22/25
Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.
Bank of America Securities Analyst forecast on GILD
Tim AndersonBank of America Securities
Bank of America Securities
$126
Buy
12.04%
Upside
Reiterated
06/06/25
Bank of America Securities Keeps Their Buy Rating on Gilead Sciences (GILD)
Jefferies Analyst forecast on GILD
Michael YeeJefferies
Jefferies
$130
Buy
15.60%
Upside
Reiterated
06/04/25
Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)We hosted mgmt to discuss the Len PrEP opportunity + pipeline ahead...co noted cont'd good dialog and on track for FDA approval (PDUFA 6/19) + lining up reimbursement over next 6-12m to support launch. Mgmt noted sig pot'l in swapping current pts (accretive to #s) + new pts not yet on PrEP - and investors catching on to even new 1x yearly LEN now starting Phase III (another bullish oppt'y). We predict likely on-time FDA approval and solid launch driving upside. Mgmt sounds positive on the lenacapavir PrEP launch -- with June 19th PDUFA just a few weeks out - co notes (1) things are moving according to plan and on track for a pot'l on time approval. (2) Co says they are launch ready w/ teams in place and on lining up reimbursement ~6mos for 75% access and 12 mos to reach 90%.
Morgan Stanley Analyst forecast on GILD
Terence FlynnMorgan Stanley
Morgan Stanley
$135
Buy
20.04%
Upside
Reiterated
06/03/25
Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects
Citi
$125
Buy
11.15%
Upside
Reiterated
06/02/25
Gilead Sciences: Promising Advancements in Cancer Treatment Bolster Buy Rating
TD Cowen
$110
Buy
-2.19%
Downside
Reiterated
06/02/25
TD Cowen Sticks to Its Buy Rating for Gilead Sciences (GILD)
Oppenheimer Analyst forecast on GILD
Matthew BieglerOppenheimer
Oppenheimer
$125
Buy
11.15%
Upside
Reiterated
06/02/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on GILD
Asthika GoonewardeneTruist Financial
Truist Financial
Hold
Reiterated
06/02/25
Gilead Sciences (GILD) Gets a Hold from Truist Financial
Leerink Partners Analyst forecast on GILD
Daina GrayboschLeerink Partners
Leerink Partners
$115
Buy
2.26%
Upside
Reiterated
06/02/25
Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value
DBS
$125
Buy
11.15%
Upside
Reiterated
05/30/25
Gilead Sciences: Strong Market Position and Growth Potential Justify Buy Rating
Wells Fargo Analyst forecast on GILD
Mohit BansalWells Fargo
Wells Fargo
$140
Buy
24.49%
Upside
Reiterated
05/22/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham
Hold
Reiterated
05/21/25
Needham Sticks to Their Hold Rating for Gilead Sciences (GILD)
BMO Capital Analyst forecast on GILD
Evan SeigermanBMO Capital
BMO Capital
$120
Buy
6.70%
Upside
Reiterated
05/15/25
Anito-cel Updates Maintain Competitive Edge - Potential 2026 Launch to Come
Argus Research Analyst forecast on GILD
Jasper HellwegArgus Research
Argus Research
$120
Buy
6.70%
Upside
Reiterated
05/05/25
Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Rezolute (RZLT)
Mizuho Securities Analyst forecast on GILD
Salim SyedMizuho Securities
Mizuho Securities
$100$117
Buy
4.04%
Upside
Reiterated
05/02/25
Gilead Sciences (GILD) Gets a Buy from Mizuho Securities
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GILD
TipRanks AITipRanks
Not Ranked
TipRanks
$119
Buy
5.82%
Upside
Reiterated
05/22/25
Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.
Bank of America Securities Analyst forecast on GILD
Tim AndersonBank of America Securities
Bank of America Securities
$126
Buy
12.04%
Upside
Reiterated
06/06/25
Bank of America Securities Keeps Their Buy Rating on Gilead Sciences (GILD)
Jefferies Analyst forecast on GILD
Michael YeeJefferies
Jefferies
$130
Buy
15.60%
Upside
Reiterated
06/04/25
Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)We hosted mgmt to discuss the Len PrEP opportunity + pipeline ahead...co noted cont'd good dialog and on track for FDA approval (PDUFA 6/19) + lining up reimbursement over next 6-12m to support launch. Mgmt noted sig pot'l in swapping current pts (accretive to #s) + new pts not yet on PrEP - and investors catching on to even new 1x yearly LEN now starting Phase III (another bullish oppt'y). We predict likely on-time FDA approval and solid launch driving upside. Mgmt sounds positive on the lenacapavir PrEP launch -- with June 19th PDUFA just a few weeks out - co notes (1) things are moving according to plan and on track for a pot'l on time approval. (2) Co says they are launch ready w/ teams in place and on lining up reimbursement ~6mos for 75% access and 12 mos to reach 90%.
Morgan Stanley Analyst forecast on GILD
Terence FlynnMorgan Stanley
Morgan Stanley
$135
Buy
20.04%
Upside
Reiterated
06/03/25
Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects
Citi
$125
Buy
11.15%
Upside
Reiterated
06/02/25
Gilead Sciences: Promising Advancements in Cancer Treatment Bolster Buy Rating
TD Cowen
$110
Buy
-2.19%
Downside
Reiterated
06/02/25
TD Cowen Sticks to Its Buy Rating for Gilead Sciences (GILD)
Oppenheimer Analyst forecast on GILD
Matthew BieglerOppenheimer
Oppenheimer
$125
Buy
11.15%
Upside
Reiterated
06/02/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on GILD
Asthika GoonewardeneTruist Financial
Truist Financial
Hold
Reiterated
06/02/25
Gilead Sciences (GILD) Gets a Hold from Truist Financial
Leerink Partners Analyst forecast on GILD
Daina GrayboschLeerink Partners
Leerink Partners
$115
Buy
2.26%
Upside
Reiterated
06/02/25
Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value
DBS
$125
Buy
11.15%
Upside
Reiterated
05/30/25
Gilead Sciences: Strong Market Position and Growth Potential Justify Buy Rating
Wells Fargo Analyst forecast on GILD
Mohit BansalWells Fargo
Wells Fargo
$140
Buy
24.49%
Upside
Reiterated
05/22/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham
Hold
Reiterated
05/21/25
Needham Sticks to Their Hold Rating for Gilead Sciences (GILD)
BMO Capital Analyst forecast on GILD
Evan SeigermanBMO Capital
BMO Capital
$120
Buy
6.70%
Upside
Reiterated
05/15/25
Anito-cel Updates Maintain Competitive Edge - Potential 2026 Launch to Come
Argus Research Analyst forecast on GILD
Jasper HellwegArgus Research
Argus Research
$120
Buy
6.70%
Upside
Reiterated
05/05/25
Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Rezolute (RZLT)
Mizuho Securities Analyst forecast on GILD
Salim SyedMizuho Securities
Mizuho Securities
$100$117
Buy
4.04%
Upside
Reiterated
05/02/25
Gilead Sciences (GILD) Gets a Buy from Mizuho Securities
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

1 Month
xxx
Success Rate
20/30 ratings generated profit
67%
Average Return
+3.00%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.00% per trade.
3 Months
xxx
Success Rate
21/30 ratings generated profit
70%
Average Return
+3.73%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.73% per trade.
1 Year
Chris SchottJ.P. Morgan
Success Rate
14/16 ratings generated profit
88%
Average Return
+22.80%
reiterated a buy rating 2 months ago
Copying Chris Schott's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +22.80% per trade.
2 Years
xxx
Success Rate
16/16 ratings generated profit
100%
Average Return
+32.81%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
42
43
56
48
40
Hold
13
10
15
10
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
53
71
58
49
In the current month, GILD has received 40 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 120.47.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $1.96 with a range of $1.86 to $2.25. The previous quarter’s EPS was $1.81. GILD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.
Next quarter’s earnings estimate for GILD is $1.96 with a range of $1.86 to $2.25. The previous quarter’s EPS was $1.81. GILD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $6.96B with a range of $6.74B to $7.27B. The previous quarter’s sales results were $6.65B. GILD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.35% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.
Next quarter’s sales forecast for GILD is $6.96B with a range of $6.74B to $7.27B. The previous quarter’s sales results were $6.65B. GILD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.35% of the time in the same period. In the last calendar year GILD has Outperformed its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 120.47.
    What is GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 7.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GILD a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s price target?
            The average price target for Gilead Sciences is 120.47. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $92.00. The average price target represents 7.12% Increase from the current price of $112.46.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of GILD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis